OXALIPLATIN "EBEWE" 150mg/30ml Infusion/Powder for

What is OXALIPLATIN "EBEWE" 150mg/30ml

OXALIPLATIN "EBEWE" 150mg/30ml is an injectable chemotherapy drug that contains Oxaliplatin, a platinum-based antineoplastic agent. It is used as part of combination therapy for various stages of colorectal cancer.

• Generic Name: Oxaliplatin
• Form: Powder for concentrate for solution for infusion
• Strength: 150 mg per vial, to be reconstituted before use
• Primary Indication: Treatment of advanced and metastatic colorectal cancer, often combined with fluoropyrimidines (e.g., 5-FU)
• Pharmacological Class: Alkylating-like agent (platinum analog)

This medicine is part of the FOLFOX regimen (5-fluorouracil + leucovorin + oxaliplatin) and is known to enhance treatment response in patients with colon or rectal cancer, especially after surgical resection or in cases with metastatic spread.

How to use OXALIPLATIN "EBEWE" 150mg/30ml

The administration of Oxaliplatin should always be conducted in a clinical environment by professionals trained in chemotherapy. The powder must be reconstituted and diluted before infusion.

• Reconstitution: Dissolve the powder using 5% glucose solution (never sodium chloride) to create a concentrate.
• Dilution: Further dilute the concentrate in 250–500 ml of 5% glucose for infusion.
• Administration Route: Intravenous infusion only; do not administer as a bolus injection.
• Infusion Time: Typically infused over 2–6 hours, depending on patient tolerance and protocol.
• Schedule: Administered once every two weeks as part of a chemotherapy cycle.
• Supportive Care: Antiemetics should be given prior to infusion to prevent nausea/vomiting.

Ensure compatibility with other chemotherapy agents when mixed or administered sequentially. Close monitoring for hypersensitivity reactions and neuropathy is essential during administration.

Mode of Action OXALIPLATIN "EBEWE" 150mg/30ml

Oxaliplatin exerts its antineoplastic effect through disruption of DNA replication and transcription, leading to cancer cell death.

• DNA Binding: Forms platinum-DNA adducts which interfere with DNA synthesis and repair mechanisms.
• Crosslink Formation: Causes intra- and inter-strand DNA crosslinks, preventing DNA separation and replication.
• Induction of Apoptosis: Damaged DNA triggers apoptosis in rapidly dividing cancer cells.
• Cell Cycle Interruption: Inhibits progression through S and G2/M phases of the cell cycle.
• Improved Tolerance: The DACH (diaminocyclohexane) carrier in Oxaliplatin contributes to greater efficacy in resistant tumors compared to cisplatin.

This mechanism is especially potent when used in combination with fluoropyrimidines, enhancing overall cytotoxic impact on malignant cells.

OXALIPLATIN "EBEWE" 150mg/30ml Interactions OXALIPLATIN "EBEWE" 150mg/30ml

Oxaliplatin may interact with various medications, potentially increasing toxicity or reducing effectiveness. Always inform your doctor of all concurrent treatments.

• Aminoglycoside Antibiotics: May increase risk of nephrotoxicity and ototoxicity.
• Other Platinum Agents: Concurrent use with cisplatin or carboplatin can lead to cumulative toxicity.
• Live Vaccines: Immunosuppression caused by chemotherapy increases risk of severe infection; avoid vaccines like yellow fever.
• Anticoagulants: May increase risk of bleeding, particularly in patients with mucositis or thrombocytopenia.
• Nephrotoxic Agents: Co-administration with NSAIDs or amphotericin B can worsen renal function.

Drug interaction management involves close clinical supervision and often requires preemptive lab testing and dose adjustments.

Dosage of OXALIPLATIN "EBEWE" 150mg/30ml

Dosage is tailored based on the patient’s body surface area (BSA) and clinical condition. Oxaliplatin is not used as monotherapy but in combination with other drugs.

• Standard Dose: 85 mg/m² IV infusion every 2 weeks as part of the FOLFOX regimen.
• Dose Adjustments: Required in cases of:
  • Renal impairment
  • Severe neurotoxicity
  • Hematologic suppression (e.g., neutropenia or thrombocytopenia)
• Duration of Treatment: Usually given for 6–12 cycles depending on clinical goals (adjuvant vs. metastatic).
• Premedication: Includes antiemetics and possibly corticosteroids to reduce nausea and hypersensitivity risks.
• Maximum Tolerated Cumulative Dose: Limited by peripheral neuropathy, which is dose- and duration-dependent.

All dosages must be calculated and confirmed by the oncologist or clinical pharmacist. Never alter chemotherapy dosing without medical consultation.

Possible side effects of OXALIPLATIN "EBEWE" 150mg/30ml

Side effects of Oxaliplatin can range from mild discomfort to serious complications. Supportive care and early recognition can help manage these effects effectively.

• Very Common Side Effects:
  • Peripheral sensory neuropathy (especially cold-induced)
  • Nausea and vomiting
  • Fatigue and weakness
  • Neutropenia, anemia, and thrombocytopenia
• Less Common but Serious Effects:
  • Hypersensitivity reactions (fever, rash, anaphylaxis)
  • Hepatotoxicity (elevated liver enzymes)
  • Pulmonary toxicity (rare interstitial lung disease)
  • Persistent or disabling neurotoxicity
• Gastrointestinal Issues: Stomatitis, diarrhea, and abdominal pain

Notify your healthcare provider immediately if you develop difficulty breathing, severe weakness, mouth ulcers, or persistent numbness.

OXALIPLATIN "EBEWE" 150mg/30ml Contraindications OXALIPLATIN "EBEWE" 150mg/30ml

Certain medical conditions and patient factors contraindicate the use of Oxaliplatin due to safety concerns.

• Known Allergy: Hypersensitivity to Oxaliplatin or other platinum-based compounds.
• Pregnancy: Contraindicated due to fetal harm; use only if benefits outweigh risks in life-threatening situations.
• Lactation: Breastfeeding should be avoided during treatment due to potential risk to the infant.
• Severe Renal Impairment: Increases risk of toxicity; use cautiously with adjusted dose if unavoidable.
• Pre-existing Neuropathy: May worsen peripheral neuropathy, especially with cumulative dosing.

Pre-treatment evaluation should include complete blood counts, renal and liver function tests, and neurologic assessment. Delay or adjust treatment in case of unresolved toxicities.

Storage of OXALIPLATIN "EBEWE" 150mg/30ml

Proper storage of Oxaliplatin ensures its potency and safety. Follow pharmaceutical storage protocols strictly.

• Before Reconstitution:
  • Store between 2°C and 8°C (refrigerated)
  • Keep in the original packaging to protect from light
  • Do not freeze
• After Reconstitution:
  • Use immediately when possible
  • Can be stored for up to 24 hours at 2–8°C if necessary
  • Must be further diluted in 5% glucose before infusion
• Disposal: Must be handled as cytotoxic waste and discarded according to institutional guidelines

Always handle with gloves and other protective equipment. Avoid contact with skin or mucous membranes. Use designated biohazard containers for disposal.